Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927695 | 0.85 | TAAR1 (0.57) | TAAR1DAOSLC6A3IDO1AGXT | |
| SCHEMBL777783 | 0.82 | TAAR1 (0.48) | TAAR1DAOIDO1AGXTMEN1 | |
| SCHEMBL4881416 | 0.81 | TAAR1 (0.58) | TAAR1DAOSLC6A3IDO1AGXT | |
| SCHEMBL2239914 | 0.81 | TAAR1 (0.53) | TAAR1DAOSLC6A3IDO1AGXT | |
| SCHEMBL5503782 | 0.81 | NOS1 (0.50) | TAAR1SLC6A3SLC6A4 | |
| SCHEMBL5500434 | 0.81 | MPO (0.48) | TAAR1 | |
| SCHEMBL778663 | 0.80 | DAO (0.38) | DAOIDO1NR3C2 | |
| SCHEMBL9477879 | 0.79 | MGLL (0.58) | TAAR1IDO1DRD2MGLL | |
| SCHEMBL3255075 | 0.79 | TAAR1 (0.55) | TAAR1MEN1KMT2A | |
| SCHEMBL6988122 | 0.79 | TAAR1 (0.54) | TAAR1DAOSLC6A3NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216988-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | claimed |
| CN-104523668-B | High-purity 2- [4- (3-or 2-fluorobenzyloxy) benzylamino ] propanamides and use thereof | 纽朗制药有限公司 | 2020-06-09 | — | — | CN | disclosed |
| US-9343777-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-05-17 | — | — | US | disclosed |
| US-9252457-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-02-02 | — | — | US | disclosed |
| US-9216988-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130190288-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20120177988-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190288-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | RORA, RORC, RORB | TAAR1 607/4885DAO 4461/4885SLC6A3 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.